¶ Complement System
¶ Introduction
The complement system is a network of over 30 soluble and membrane-bound [/proteins/proteins) that constitute a major arm of innate [1]
immunity. In the brain, complement proteins are produced locally by [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX-- and [microglia[/[DOI[/[DOI[/[DOI[/[DOI[/[DOI[/[DOI[/[DOI[/DOI" title="Tenner AJ, et al. Complement in the brain. Trends Immunol. 2018;39(8):622-639. DOI
complement [genes[/[genes[/[genes[/[genes[/[genes[/[genes[/[genes[/[genes[/genes (CLU, CR1, C4A/C4B) as risk loci for [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, positioning the complement system as both a
biomarker and a therapeutic target in neurodegeneration [2].
¶ Overview
The complement system represents a critical pathological mechanism in neurodegenerative /diseases), particularly
[complement-mediated synapse loss[/mechanisms/[complement-mediated-synapse-loss[/mechanisms/[complement-mediated-synapse-loss[/mechanisms/[complement-mediated-synapse-loss[/mechanisms/[complement-mediated-synapse-loss--TEMP--/mechanisms)--FIX-- — the strongest pathological correlate of cognitive decline
in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, exceeding even amyloid plaque burden and neurofibrillary tangle density [3]. Originally
discovered as a normal developmental pruning mechanism, inappropriate reactivation of complement-dependent synaptic elimination in the adult
brain has emerged as a major contributor to cognitive decline in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, Huntington's Disease, [multiple
sclerosis[/diseases/[multiple-sclerosis[/diseases/[multiple-sclerosis[/diseases/[multiple-sclerosis[/diseases/[multiple-sclerosis--TEMP--/diseases)--FIX--, Frontotemporal Dementia, and other neurodegenerative conditions [4].
The complement system consists of over 30 proteins that work in a cascade to eliminate pathogens and damaged cells [1]. In the brain, complement is produced by [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--, [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX--, and particularly [microglia[/[DOI[/[DOI[/[DOI[/[DOI[/[DOI[/[DOI[/[DOI[/DOI" title="Rogers J, et al. Complement activation by beta-amyloid in Alzheimer's Disease. Proc Natl Acad Sci. 1992;89(21):10016-10020. [DOI)">5
- Damaged or apoptotic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--
- Weakened or "tagged" synapses
C1q binding activates C1r/C1s proteases, which cleave C4 and C2 to form the classical C3 convertase (C4b2a). The classical pathway is the most relevant complement activation route in Alzheimer's Disease and developmental synaptic pruning.
In Alzheimer's Disease, soluble [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- oligomers — rather than fibrillar plaques — are the primary trigger for aberrant C1q deposition on synapses. C1q protein levels are dramatically increased (up to 80-fold) in the AD [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX-- compared to age-matched controls, with increases detectable before visible plaque pathology [6].
¶ Lectin Pathway
The lectin pathway is triggered by mannose-binding lectin (MBL) and ficolins recognizing carbohydrate patterns on damaged cells and pathogens. MBL-associated serine proteases (MASP-1, MASP-2) cleave C4 and C2, generating the same C3 convertase as the classical pathway. MBL has been shown to bind [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- and contribute to complement activation in AD brain tissue [7].
¶ Alternative Pathway
The alternative pathway is constitutively active at low levels through spontaneous C3 hydrolysis ("tickover"). C3b deposited on surfaces recruits factor B, which is cleaved by factor D to form the alternative C3 convertase (C3bBb), amplified by properdin. This pathway serves as an amplification loop for both the classical and lectin pathways and is regulated by factors H and I [8].
¶ Terminal Pathway and Membrane Attack Complex
All three pathways converge at C3, which is cleaved to generate:
- C3b: Opsonin that tags targets for phagocytosis via complement receptor 3 (CR3/CD11b-CD18) on [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--:89. [DOI)" title="Bacsne MB, et al. Sublytic membrane attack complex in neurodegeneration. Acta Neuropathol Commun. 2021;9(1):89. [DOI)">9.
¶ Molecular Mechanism of Complement-Mediated Synapse Loss
¶ The Classical Complement Cascade at Synapses
In the healthy developing brain, the classical complement pathway prunes excess synapses during critical periods of circuit refinement. This normal process is tightly regulated and largely quiescent in the adult brain. However, in neurodegenerative disease, the cascade becomes pathologically reactivated [4].
The molecular sequence proceeds as follows:
-
C1q deposition: C1q, the recognition molecule of the classical complement pathway, is aberrantly upregulated and deposited onto synaptic terminals. In Alzheimer's Disease, soluble [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- (Aβ) oligomers drive region-specific C1q upregulation, particularly in the [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX-- and [entorhinal [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX-- — areas that are most vulnerable to early synaptic loss [6].
-
C1 complex activation: C1q binds to the synaptic surface and recruits C1r and C1s serine proteases, forming the active C1 complex. This triggers the enzymatic cascade that cleaves C4 and C2 to form C3 convertase (C4b2a).
-
C3 opsonization: C3 convertase cleaves C3 into C3a (an anaphylatoxin promoting inflammation) and C3b, which covalently binds to the synaptic surface. C3b is further cleaved to iC3b, which serves as the primary "eat-me" signal recognized by phagocytic cells.
-
CR3-dependent phagocytosis: [Microglia[/[DOI[/[DOI[/[DOI[/[DOI[/[DOI[/[DOI[/[DOI[/DOI">10.
¶ Astrocytic Contributions
[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX-- are the primary source of C3 in the mouse brain under physiological conditions. In tau] pathology] models, [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX-- contribute substantially to complement-dependent synapse elimination, acting alongside [microglia[/[cell[/[cell[/[cell[/[cell[/[cell[/[cell[/[cell[/cell types/cell-types) coordinate the synaptic destruction program [11].
¶ Complement-Mediated Synaptic Pruning
¶ Developmental Role
During normal brain development, complement eliminates excess synapses to refine neural circuits. C1q localizes to weaker or less active
synapses, triggers C3 activation, and C3b/iC3b deposition opsonizes those synapses for [microglial
phagocytosis[/mechanisms/[microglial-phagocytosis[/mechanisms/[microglial-phagocytosis[/mechanisms/[microglial-phagocytosis[/mechanisms/[microglial-phagocytosis--TEMP--/mechanisms)--FIX-- via CR3 [10]. This process is essential for
proper circuit maturation — C1q or C3 knockout mice retain excess retinogeniculate synapses [12].
¶ Reactivation in Neurodegeneration
In the adult brain, the developmental pruning pathway is normally downregulated. However, it becomes aberrantly reactivated in neurodegenerative diseases:
- C1q upregulation: C1q expression increases 10–80-fold in Alzheimer's Disease brain and is elevated before overt plaque deposition [6]
- Synapse opsonization: C1q and C3 localize to synapses in the [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX-- and [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--, tagging them for elimination
- Microglial phagocytosis: [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--:10016-10020. [DOI)" title="Rogers J, et al. Complement activation by beta-amyloid in Alzheimer's Disease. Proc Natl Acad Sci. 1992;89(21):10016-10020. [DOI)">5. While complement-mediated opsonization may initially facilitate microglial clearance of [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX--, chronic activation sustains neuroinflammation and drives bystander synaptic damage.
¶ Tau Pathology
Emerging evidence links complement to tau pathology:
- C1q levels in cerebrospinal fluid are associated with tau burden and mediate the association between [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- and tau accumulation [14]
- C3 knockout reduces tau-dependent neurodegeneration in mouse models
- Complement activation may amplify tau spreading by promoting microglial activation and release of inflammatory cytokines
- C1q is associated with neuroinflammation and mediates the statistical association between amyloid and tau pathology, suggesting complement bridges the two hallmark AD pathologies
¶ Region-Specific Vulnerability
Complement activation mirrors the topographic pattern of early AD, with the [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX--, entorhinal [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--, and [prefrontal cortex[/brain-regions/[prefrontal-cortex[/brain-regions/[prefrontal-cortex[/brain-regions/[prefrontal-cortex[/brain-regions/[prefrontal-cortex--TEMP--/brain-regions)--FIX-- showing the highest complement burden. This region-specific pattern corresponds to the areas most vulnerable to early synaptic loss.
¶ ApoE4 and Complement
APOE4 enhances complement activation in the brain:
- ApoE4 is less effective at suppressing C1q-mediated complement activation than ApoE3
- ApoE4 carriers show increased C1q deposition at synapses
- APOE4 may reduce complement inhibitory factor expression, leaving synapses more vulnerable to complement-mediated destruction [15]
- CR1 (complement receptor 1) is an AD risk gene that may interact with ApoE to modulate [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- clearance
¶ TREM2
[TREM2[/genes/[trem2[/genes/[trem2[/genes/[trem2[/genes/[trem2--TEMP--/genes)--FIX-- — an AD risk gene expressed on [microglia[/entities/microglia**: Complement regulator; inhibits MAC [formation[/entities/microglia**: Complement regulator; inhibits MAC [formation[/entities/microglia**: Complement regulator; inhibits MAC [formation[/entities/microglia**: Complement regulator; inhibits MAC [formation[/entities//entities/microglia**: Complement regulator; inhibits MAC [formation[/entities//entities//entities/microglia**: Complement regulator; inhibits MAC [formation[/entities//entities//entities//entities/microglia**: Complement regulator; inhibits MAC [formation[/entities//entities//entities//entities//entities/microglia**: Complement regulator; inhibits MAC [formation](/entities//entities//entities//entities//entities/microglia**: Complement regulator; inhibits MAC formation)
- CR1 (complement receptor 1): Regulates C3b/C4b activity
- C4A/C4B: Copy number variants affect complement activation levels
- PILRA: Modulates microglial complement responses [2]
¶ Complement in Other Neurodegenerative Diseases
¶ Parkinson's Disease
C1q and C3 are upregulated in the [substantia nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra--TEMP--/brain-regions)--FIX-- in [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, and [alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX-- aggregates activate the classical complement pathway. C4 exacerbates astrocyte-mediated neuroinflammation and promotes alpha [18]. C3aR and C5aR1 signaling contribute to dopaminergic neuron loss, and CR3 knockout mice are protected from toxin-induced parkinsonism.
¶ Huntington's Disease
Huntington's Disease features early complement-mediated synapse loss in the corticostriatal circuit. [microglia[/[DOI[/[DOI[/[DOI[/[DOI[/[DOI[/[DOI[/[DOI[/DOI">19. C1q and C3 are elevated in the [striatum[/brain-regions/[striatum[/brain-regions/[striatum[/brain-regions/[striatum[/brain-regions/[striatum--TEMP--/brain-regions)--FIX-- of HD patients and mouse models.
¶ Amyotrophic Lateral Sclerosis
In ALS, complement activation occurs at the neuromuscular junction and in spinal [motor neurons[/cell-types/[motor-neurons[/cell-types/[motor-neurons[/cell-types/[motor-neurons[/cell-types/[motor-neurons--TEMP--/cell-types)--FIX--. C1q, C3, and MAC are deposited at motor endplates before symptom onset in SOD1 mouse models. The C5aR1 antagonist PMX205 extends survival and improves motor function in ALS models [20].
¶ Multiple Sclerosis
In multiple sclerosis and other demyelinating diseases, complement-mediated synapse loss occurs at demyelinated lesions. Targeted complement inhibition at synapses prevents microglial synaptic engulfment and synapse loss in demyelinating disease models [21].
¶ Frontotemporal Dementia
Complement activation drives synaptic loss in FTD models, particularly those involving tau pathology and [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- proteinopathy. C1q-dependent astrocyte and microglial synapse elimination has been demonstrated in tau transgenic models relevant to FTD.
¶ Therapeutic Strategies
¶ C1q Inhibitors
- ANX005 (Annexon Biosciences): Humanized monoclonal antibody against C1q; blocks classical pathway initiation. In a Phase 2 clinical trial in Huntington's Disease, ANX005 showed evidence of sustained improvement in patients with elevated baseline complement activity [22].
- Peptide antagonists: Smaller molecules targeting C1q binding sites, potentially improved CNS penetration
¶ C3 Inhibitors
- Pegcetacoplan (compstatin analog, approved for PNH): Prevents C3 activation and all downstream effects
- C3-targeted [gene therapy[/treatments/[gene-therapy[/treatments/[gene-therapy[/treatments/[gene-therapy[/treatments/[gene-therapy--TEMP--/treatments)--FIX--: Intrathecal or AAV-delivered approaches under preclinical investigation
- Genetic deletion of C3 in AD mouse models rescues synapse loss and improves cognitive performance [13]
¶ CR3 Antagonists
Blocking the microglial complement receptor CR3 directly prevents phagocytic engulfment of complement-tagged synapses. CR3 knockout mice are protected from [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX---induced synapse loss [10].
¶ C5/C5a Pathway Inhibitors
- Eculizumab/Ravulizumab (anti-C5 antibodies, approved for PNH/aHUS): Block terminal complement and MAC formation
- PMX205 (C5aR1 antagonist): Orally bioavailable, crosses the [BBB[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX--; improves outcomes in ALS and HD mouse models [20]
- Avacopan (C5aR1 antagonist, approved for ANCA vasculitis): Potential CNS applications being explored
¶ Challenges
-
[BBB[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX-- penetration: Most complement inhibitors are large proteins with poor CNS access, necessitating intrathecal delivery or small-molecule alternatives
-
Beneficial complement functions: Complete complement inhibition increases infection risk and may impair microglial clearance of debris and aggregated proteins
-
Timing of intervention: Complement inhibition may be most effective early in disease, before extensive neuronal loss
-
Pathway specificity: Selective targeting of the classical pathway (C1q) may be preferable to global complement inhibition
-
CNS penetration: Many inhibitors don't cross the [blood-brain barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX--
-
Normal immune function: Complete inhibition increases infection risk
-
Timing: intervention may need to be early
-
Specificity: Balancing inhibition with normal functions## Relationship to Other Mechanisms/mechanisms)
Complement-mediated synapse loss intersects with multiple pathological pathways in neurodegeneration:
- neuroinflammation: Complement activation generates anaphylatoxins (C3a, C5a) that amplify microglial and astrocytic inflammatory responses [1]
- [Amyloid] pathology: [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- oligomers trigger complement deposition, while complement activation may impair microglial amyloid clearance [5]
- [Tau[/entities/[tau-protein[/entities/[tau-protein[/entities/[tau-protein[/entities/[tau-protein--TEMP--/entities)--FIX--(/proteins/tau pathology: C1q mediates the association between amyloid and tau [14]
- Synaptic dysfunction: Sublytic MAC deposition causes calcium influx and synaptic signaling disruption [9]
- Disease-associated microglia: DAM transition involves upregulation of complement receptors and phagocytic machinery [16]
¶ Biomarker Potential
Complement activation products in cerebrospinal fluid and plasma show promise as neurodegeneration biomarkers:
- CSF C3a/C5a: Elevated in AD and correlate with disease severity and progression
- CSF C1q: Mediates the association between amyloid and tau pathology [14]
- Plasma complement factors: C3, factor H, and clusterin levels are altered in AD
¶ APOE and Complement
[APOE:622-639. . . DOI
¶ See Also
- [neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation--TEMP--/mechanisms)--FIX-- - The broader inflammatory response in neurodegeneration
- [microglia[/cell-types/[microgliahttps[/cell-types/[microgliahttps[/cell-types/[microgliahttps[/cell-types/[microgliahttps--TEMP--/cell-types)--FIX--
/pubmed.ncbi.nlm.nih.gov/) - UniProt: C3 Complement
- NCBI: Complement System
¶ Background
The study of Complement System has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
¶ External Links
- PubMed - Biomedical literature
- Alzheimer's Disease Neuroimaging Initiative - Research data
- Allen Brain Atlas - Brain gene expression data
¶ Brain Atlas Resources
- Allen Human Brain Atlas: Complement System expression search
- Allen Mouse Brain Atlas: Complement System search
- Allen Cell Type Atlas: Transcriptomic cell type reference
- BrainSpan Developmental Transcriptome: Complement System developmental expression
¶ References
- Chen WT et al., Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer's Disease (2020)
- Zhao H et al., The activation of microglia by the complement system in neurodegenerative diseases (2025)
- Fatoba O, Itokazu T, Yamashita T, Complement cascade functions during brain development and neurodegeneration (2022)
- Matera A et al., Microglial lipid phosphatase SHIP1 limits complement-mediated synaptic pruning in the healthy developing hippocampus (2025)
- Upadhya R et al., Astrocyte-derived extracellular vesicles: Neuroreparative properties and role in the pathogenesis of neurodegenerative disorders (2020)
- Vlaicu SI et al., COVID, complement, and the brain (2023)
- Magdalon J et al., Complement System in Brain Architecture and Neurodevelopmental Disorders (2020)
- Jovčevska I, Videtič Paska A, Kouter K, Complement Cascades and Brain Disorders (2025)
-
- [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- — Disease where complement activation contributes to pathology
-
- [neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation--TEMP--/mechanisms)--FIX-- — Inflammatory processes in the brain
-
- [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--/cell-types/microglia — Neuroimmune interactions database
-
- EMBO Reports — Complement in AD — Complement and Alzheimer's Disease